OV with pH-resistant envelopes, metabolic inhibitors (LDH, P13K inhibitors) + metabolic inhibitors (e.g. metformin, GLUT1 inhibitors) for TBNC (HER2+ subtypes); or FGFR inhibitors (e.g. Erdafitinib) for FGFR3-mutated bladder tumors; or IDH inhibitors + metabolic targeting for glioblastomas. Here, SLC2A1 is linked to urinary bladder neoplasm.